KUMULUS-VAPE
28.5.2019 05:59:06 CEST | Business Wire | Press release
At 11.30 am this Tuesday, May 28 2019, shares in Kumulus Vape (ISIN: FR0013419876 - symbol: MLVAP) will be listed for the first time on the Euronext Access™ market in Paris (by technical admission). Kumulus Vape is an e-merchant specializing in the sale of electronic cigarettes and related 'vaping' products (equipment, e-liquids and accessories).
The listing on the Paris stock exchange is a first for European vape companies, marking a new milestone in the performance trajectory of the company from Lyon, a pioneer in its market in an active phase of development. The aim of this move is to enable Kumulus Vape to raise brand awareness and strengthen its presence on the domestic market.
55,000 shares will be offered for sale on the first day of market trading. This admission to the Euronext Access™ market constitutes a first step, prior to a possible transfer of Kumulus Vape shares to the Euronext Growth® market. The company seeks to introduce a dynamic of shares changing hands that could account for between 5 and 10% of the capital.
Established in 2012, Kumulus Vape is one of the main French online sites for the sale of vaping products (equipment, e-liquid, DIY1 ). With its broad range, comprising over 6,000 items, it offers products for both 'beginners' and vaping experts. As a committed player in combating tobacco and an advocate for the vaping sector, Kumulus Vape offers an unequalled choice of high-performing vaping products at low prices.
In 2018, Kumulus Vape's turnover was €6.5 million, up 116% on 2017. The EBITDA exceeded the €400,000 mark (+128% on 2017), with a net income of nearly €300,000 (+106%). In the first quarter of 2019, turnover rose by 96% to €2.3 million.
Kumulus Vape has a clear aim: to become one of the French leaders in 100% e-commerce vaping in the next three years.
Operating procedures
Listing market:
Euronext Access™
ISIN
:
FR0013419876
Symbol
: MLVAP
Registration procedure
:
technical admission
Number of shares in company capital
:
1,988,000
Number of shares sold on the day of listing
: 55,000
Sale
price per share
: €2.12
Valuation at time of listing
:
€4,214,560
Start of trading
: May 28, 2019
Eligible
for PEA (equity savings plan) and SME PEA
: yes
The operation does not require authorization from the French Financial Markets Authority (AMF). The information document has therefore not been approved by the AMF. The information document is available free of charge from the head office of Kumulus Vape. It may be downloaded from www.kumulusvape.fr/investisseurs . Please note that companies admitted to Euronext Access are not subject to the same rules as companies on the regulated market. Instead, they are subject to a smaller set of rules that is suitable for small businesses experiencing growth. The risk associated with an investment on Euronext Access may therefore be greater than investing in a company on the regulated market.
Partners in the operation
|
Atout Capital |
Consultant and listing sponsor |
|
|
Lamy Lexel |
Legal advice |
|
|
Mazars |
Auditors |
|
|
Actifin |
Financial communications |
|
About Kumulus Vape
Established in 2012, Kumulus Vape is one of the leading French distributors of e-cigarettes and e-liquids . With www.kumulusvape.fr , its website for individuals, and its wholesale business for specialist boutiques, the Company is positioned on both the B2C and B2B markets. Kumulus Vape's turnover rose to €6.5 million in 2018, representing a growth of 116% on 2017. Kumulus Vape is based in Corbas, just a few minutes from the south of Lyon, and currently has about 25 employees.
1 Do It Yourself: e-liquid base that people can use to create their own blends
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005309/en/
Contact:
KUMULUS VAPE Director of Communications Vincent Baudoin v.baudoin@kumulusvape.fr Tel.: 06 10 84 52 59
ACTIFIN Press relations Aminata Doucouré adoucoure@actifin.fr Tel.: 01 56 88 11 23
ACTIFIN Financial communications Julien Mouret jmouret@actifin.fr Tel.: 01 56 88 11 14
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom